Literature DB >> 7845418

Bioavailability of fluconazole in the skin after oral medication.

A Wildfeuer1, J Faergemann, H Laufen, G Pfaff, T Zimmermann, H P Seidl, P Lach.   

Abstract

Fluconazole is an antimycotic drug which until now has been used mostly in the systemic therapy of yeast infections. We have now demonstrated the presence of this drug in various skin structures. After administration of 50 mg of fluconazole per day for 12 days to healthy volunteers, the following mean drug concentrations were measured: serum 1.81 micrograms ml-1, sweat 4.58 micrograms ml-1, dermis-epidermis (without stratum corneum) 2.77 micrograms g-1 and stratum corneum 73 micrograms g-1. Thus, 4 h after the last dose the antimycotic attains a 40-fold higher concentration in the stratum corneum than in serum. One week after ending the oral treatment, 5.8 micrograms g-1 fluconazole was present in stratum corneum. After daily ingestion of 200 mg of fluconazole for 5 days there was a further increase in the mean concentration of fluconazole in stratum corneum, to 127 micrograms g-1. Even 4-5 months after completing the oral treatment, fluconazole was detectable in the head hair and toenails of healthy volunteers. Fluconazole is eliminated from the stratum corneum about 2-3 times more slowly than from serum or plasma. After oral administration fluconazole evidently accumulated rapidly and intensively into the stratum corneum. The concentrations then attained or exceeded the in vitro minimal inhibitory concentrations of fluconazole for most of the dermatophytes and yeasts which are involved in cutaneous mycoses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7845418     DOI: 10.1111/j.1439-0507.1994.tb00788.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  18 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Onychomycosis. Going for cure.

Authors:  A K Gupta; N H Shear
Journal:  Can Fam Physician       Date:  1997-02       Impact factor: 3.275

3.  Study of in vitro drug release and percutaneous absorption of fluconazole from topical dosage forms.

Authors:  Claudia Salerno; Adriana M Carlucci; Carlos Bregni
Journal:  AAPS PharmSciTech       Date:  2010-06-03       Impact factor: 3.246

Review 4.  Clinical and economic factors in the treatment of onychomycosis.

Authors:  T R Einarson; A K Gupta; N H Shear; S Arikian
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 5.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

6.  In vivo efficacy and pharmacokinetics of voriconazole in an animal model of dermatophytosis.

Authors:  D M Saunte; F Simmel; N Frimodt-Moller; L B Stolle; E L Svejgaard; M Haedersdal; C Kloft; M C Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

7.  Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques.

Authors:  Lucy Sasongko; Kenneth M Williams; Richard O Day; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

Review 8.  Treatment and prophylaxis of tinea infections.

Authors:  G E Piérard; J E Arrese; C Piérard-Franchimont
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

9.  Rapid sampling of molecules via skin for diagnostic and forensic applications.

Authors:  Sumit Paliwal; Makoto Ogura; Samir Mitragotri
Journal:  Pharm Res       Date:  2010-03-18       Impact factor: 4.200

Review 10.  Updates on the epidemiology of dermatophyte infections.

Authors:  Claus Seebacher; Jean-Philippe Bouchara; Bernard Mignon
Journal:  Mycopathologia       Date:  2008-05-14       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.